Back to Search
Start Over
Guillain-Barré syndrome after vaccination against COVID-19.
- Source :
-
The Lancet. Neurology [Lancet Neurol] 2022 Feb; Vol. 21 (2), pp. 117-119. Date of Electronic Publication: 2021 Dec 17. - Publication Year :
- 2022
-
Abstract
- Competing Interests: JYC, SP, JJ, T-SK, YJC, and H-SE declare no competing interests. J-WH has received a grant from the National Research Foundation of Korea. S-HK lectured for Bayer Schering Pharma, Genzyme, and Merck Seron; consulted for Bayer Schering Pharma, Merck Serono, Biogen, Genzyme, and Union Chimique Belge; received honoraria from Bayer Schering Pharma, Merck Serono, Genzyme, and UCB; and received a grant from the National Research Foundation of Korea. HJK received a grant from the National Research Foundation of Korea and research support from Aprilbio and Eisai; and received consultancy and speaker fees from Alexion, Aprilbio, Biogen, Celltrion, Daewoong, Eisai, GC Pharma, HanAll BioPharma, MDimune, Merck Serono, Novartis, Roche, Sanofi Genzyme, Teva-Handok, Union Chimique Belge, and Viela Bio. The Institutional Review Board of the National Cancer Center (IRB number NCC-2021–0260) approved this study and waived the requirement for informed consent because of the use of de-identified data. JYC and SP contributed equally as first authors.
Details
- Language :
- English
- ISSN :
- 1474-4465
- Volume :
- 21
- Issue :
- 2
- Database :
- MEDLINE
- Journal :
- The Lancet. Neurology
- Publication Type :
- Editorial & Opinion
- Accession number :
- 34929194
- Full Text :
- https://doi.org/10.1016/S1474-4422(21)00416-6